Or Refractory Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Or Refractory Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial evaluating ATG-010 with bortezomib and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myelom…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 study evaluating QLS32015 as monotherapy versus Pomalidomide plus Dexamethasone or Selinexor plus Dexamethasone in relapsed or refra…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Genmab's GEN3014 trial in relapsed or refractory hematologic malignancies (relapsed/refractory multiple myeloma, diffuse large B cell lympho…
-
CLINICAL_TRIALS trial_result · 2025-11-14Clinical Trial Update: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM [Phase 3]
Phase 3 trial evaluating subcutaneous versus intravenous isatuximab in combination with pomalidomide and dexamethasone for relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets [Phase 1]
An update on a Phase 1 study evaluating ABBV-453 in adults with relapsed or refractory multiple myeloma, focusing on adverse events and chan…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of ORIC-533 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma [Phase 1]
Amgen completed a Phase 1b study of OPomD for relapsed or refractory multiple myeloma, with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of N-803 in relapsed or refractory multiple myeloma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy [Phase 2]
A Phase 2 trial evaluating abatacept in combination with ixazomib citrate and dexamethasone in relapsed/refractory multiple myeloma was term…
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ABT-199 in relapsed or refractory multiple myeloma (Phase 1/Phase 2) with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) [Phase 2]
Phase 2 study of vorinostat combined with bortezomib in relapsed or refractory multiple myeloma completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-01-08Clinical Trial Update: A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers [Phase 2]
Phase 2 trial of carfilzomib plus dexamethasone in relapsed or refractory multiple myeloma was terminated at US community oncology centers; …
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. [Phase 1, Phase 2]
A Phase I/Ib-II study to determine the maximum tolerated dose of AUY922 alone and with bortezomib, with or without dexamethasone, in relapse…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide [Phase 2]
A Phase II multicenter, open-label, single-arm study evaluating pomalidomide with dexamethasone and cyclophosphamide in relapsed or refracto…